Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 5Plasma cell 2Classical hematology 2

Conditions

Multiple Myeloma 3577Neoplasms, Plasma Cell 696Lymphoma 531Lymphoma, Non-Hodgkin 480Leukemia, Lymphocytic, Chronic, B-Cell 409Hodgkin Disease 405Recurrence 404Precursor Cell Lymphoblastic Leukemia-Lymphoma 375Leukemia 373Leukemia, Myeloid, Acute 363Myelodysplastic Syndromes 331Lymphoma, Large B-Cell, Diffuse 290Lymphoma, Mantle-Cell 288Lymphoma, Follicular 284Lymphoma, B-Cell, Marginal Zone 256Burkitt Lymphoma 249Immunoglobulin Light-chain Amyloidosis 227Myeloproliferative Disorders 226Lymphoma, Large-Cell, Immunoblastic 223Neoplasms 214Hematologic Neoplasms 200Primary Myelofibrosis 186Leukemia, Myeloid, Chronic-Phase 182Leukemia, Myeloid, Accelerated Phase 173Lymphoma, T-Cell, Cutaneous 170Waldenstrom Macroglobulinemia 164Blast Crisis 162Leukemia, Myelomonocytic, Chronic 158Mycosis Fungoides 147Sezary Syndrome 146

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 1Immunoglobulins 1Hizentra 1Clavulanic Acid 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Agammaglobulinemia × Plasma cell × Clear all
NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

NCT05678621 2024-04-19

RATIONALISE

Monash University

Phase 2/3 Recruiting
300 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Agammaglobulinemia, Infections, Leukemia, Lymphoma, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡